Candida pararugosa: First ReportedBloodstream Infection in an Adult

Guy El Helou 1, Elizabeth Palavecino 2

1. Infectious Disease, Wake Forest Baptist Medical Center 2. Clinical Pathology, Wake Forest Baptist Medical Center

Corresponding author: Guy El Helou, helouguy@gmail.com
Disclosures can be found in Additional Information at the end of the article

Abstract

Candida pararugosa is a yeast that has been previously isolated in various human specimens. The first reported isolation was from human feces in 1998, with subsequent reports of positive cultures from the oral cavity where it was thought to represent colonization rather than true infection. Though it has been isolated from other human sites, its clinical significance and manifestations are poorly characterized. We report the case of a 39-year-old woman on parenteral hyperalimentation who developed post abdominal surgery sepsis and surgical wound necrotizing fasciitis. Candida pararugosa was isolated from two different blood cultures and the patient’s clinical status improved after initiation of therapy with micafungin. Though it was not clear whether sepsis was driven by the candidemia or the necrotizing fasciitis or both, this report appears to be the first case of Candida pararugosa bloodstream infection described in an adult.

Introduction

Candida pararugosa (C. pararugosa) was first described in the medical literature in 1999 by Nakase, et al. [1]. It was isolated from human feces and believed to be a colonizer of the gastrointestinal (GI) tract. Since then, additional reports in the literature have established this yeast as an occasional colonizer of the oral cavity as well [2-3]. Though subsequently isolated from various human anatomical sites and specimens [4], no case reports in the medical literature are available to correlate its isolation with clinical disease. To the best of our knowledge, this report represents the first case of C. pararugosa isolated from blood in an adult.

Case Presentation

A 39-year-old female underwent duodenal switch with biliopancreatic diversion surgery for morbid obesity in July 2016. Her post-operative course was complicated by delayed emptying of the stomach and duodeno-ileal anastomotic stricture treated by three endoscopic dilatations leading to severe weight loss and failure to thrive. A peripherally inserted central catheter (PICC) was placed in January 2017 and she was started on total parenteral nutrition (TPN). In March 2017, she underwent duodenal switch revision surgery with J-tube placement. This procedure was complicated by sepsis and necrotizing fasciitis of the surgical wound requiring broad-spectrum antibiotics (vancomycin and piperacillin/tazobactam) and repetitive incision and debridement (I&D). Despite apparent good source control, she continued to exhibit fevers and had hypotension. Central and peripheral blood cultures (BC) were obtained and her piperacillin/tazobactam was changed to meropenem. Two days later, both of her BC grew yeast
and micafungin 100 mg IV daily was started and the PICC was removed. After receiving micafungin for 48 hours, her fevers resolved and her hypotension improved. The yeast was finally identified as *C. pararugosa* with MALDI-TOF, though no GenBank/MALDI BioTyper accession could be generated. The patient was continued on micafungin as her isolate had minimal inhibitory concentration (MIC) of 8 μg/ml to fluconazole. Subsequent BC were negative and therapy was continued for two weeks after PICC removal. Dilated eye exam by ophthalmology found no evidence of ocular involvement.

**Discussion**

*C. pararugosa* is now recognized as a distinct *Candida* species different from *Candida rugosa* spp complex [5]. Though morphologically different, misidentification of this species as *Candida rugosa* (*C. rugosa*) is common when phenotypic characteristics are analyzed [5]. *C. pararugosa* has been isolated from various environmental sources and foods [6-8] and has been mentioned as a potential probiotic for its ability to resist toxic effects of bile and gastric secretions [9]. Human isolations of this yeast were initially from feces and the oral cavity [1-3], suggesting a potential role as a colonizer of the GI tract. Newer molecular studies have facilitated the identification of *C. pararugosa* from human bronchial washes, blood, urine, and vagina [4, 10]. Limited clinical data on the patients from whom the positive cultures were obtained are provided. However, there is a reference to a 6-month-old male with intrauterine growth restriction from Qatar treated with liposomal amphotericin B who died from *C. pararugosa* bloodstream infection as reported by Taj-Aldeen, et al. [10]. *C. pararugosa* has also been implicated as a potential pathogen in fingernail onychomycosis. The pathogenic role that this yeast actually plays in human disease is still uncertain. *Candida* spp. isolated from blood cultures are usually associated with high likelihood of invasive disease and high mortality. In our patient, micafungin was initiated before speciation of the yeast occurred, with subsequent clinical and hemodynamic improvement. It is possible that this improvement was the delayed effect of necrotizing fasciitis control, but the timeline of events was more compatible with control of candidemia. Our isolate’s MICs were consistent with previously reported high MIC to fluconazole and low MIC to amphotericin [4-5, 10]. MICs for the *C. pararugosa* strain isolated from our patient are listed in Table 1. Though no susceptibility breakpoints are established for *C. pararugosa*, we decided to continue with micafungin as the MIC for fluconazole was high when compared to other *Candida* spp. with established breakpoints.
<table>
<thead>
<tr>
<th>Anti-fungal agent</th>
<th>Candida pararugosa MIC&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Candida albicans resistance breakpoint&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-Fluorocytosine</td>
<td>0.12</td>
<td></td>
</tr>
<tr>
<td>Amphotericin B</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Fluconazole</td>
<td>8</td>
<td>&gt;= 8</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>0.12</td>
<td></td>
</tr>
<tr>
<td>Micafungin</td>
<td>0.06</td>
<td>&gt;= 1</td>
</tr>
</tbody>
</table>

**TABLE 1: Candida pararugosa minimal inhibitory concentration (MIC) (ug/mL) compared to Candida albicans breakpoints**

<sup>a</sup>Described in the case
<sup>b</sup>Candida albicans breakpoint from CLSI M27-S4, 2012

**Conclusions**

The goal of this report is to raise clinical awareness of heretofore uncommon pathogens detected by newer techniques such as MALDI-TOF or molecular methods. Our patient represents the first detailed clinical report of *C. pararugosa* infection in an adult. The only previously reported case of bloodstream infection with *C. pararugosa* was in a child who died despite treatment with intravenous amphotericin B. Our isolate as well as previously reported isolates exhibit high MICs to fluconazole. Though no susceptibility breakpoints are available, the generally high MICs to fluconazole warrant consideration of therapy with micafungin or another echinocandin.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained by all participants in this study. The Wake Forest University School of Medicine Institutional Review Board issued approval IRB00044240. The Wake Forest University School of Medicine Institutional Review Board has reviewed your protocol and determined that it does not meet the federal definition of research involving human subject research as outlined in the federal regulations 45 CFR 46. 45 CFR 46.102(f) defines human subjects as "a living individual about whom an investigator (whether professional or student) conducting research obtains (1) data through intervention or interaction with the individual, or (2) identifiable private information." The information you are receiving is not individually identifiable. In recent guidance published by the Office of Human Research Protections (OHRP) on the Guidance on Research Involving Coded Private Information or Biological Specimens, OHRP emphasizes the importance on what is being obtained by the investigator and states "if investigators are not obtaining either data through intervention or interaction with living individuals, or identifiable private information, then the research activity does not involve human subjects." Note that only the Wake Forest University School of Medicine IRB can make the determination for its investigators that a research study does not meet the federal definition of human subject research. Investigators do not have the authority to make an independent determination that a study does not meet the federal
requirements for human subject research. Each project requires a separate review and determination by the Board. The Board must be informed of any changes to this project, so that the Board can determine whether it continues to meet the federal requirements for human subject research. If you have any questions or concerns about this information, please feel free to contact our office at 716-4542. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**Acknowledgements**

Dr. Laura H. Bachmann who took care of the patient and Dr. James Peacock for his review of the article.

**References**